| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1008: Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments |
|
Medicine details |
|
| Medicine name | trifluridine/tipiracil (Lonsurf®) |
| Formulation | 15 mg/6.14 mg film-coated tablet, 20 mg/8.19 mg film-coated tablet 25 mg/ml concentrate for solution for infusion |
| Reference number | 5286 |
| Indication | With bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments |
| Company | Servier Laboratories Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/08/2024 |
| NICE guidance | |